Why Is Kestra Medical Technologies Stock Down Today?
Kestra grew fiscal first-quarter revenue 60% to $31.0 million and raised guidance to $141 million, but its adjusted loss widened to $0.75 a share. The stock was 7.733% lower after hours, 10 minutes after the 16:01:48 ET release.
- Fiscal Q1 2027 revenue rose 60% to $31.0 million and gross margin widened to 56.5% from 45.7%.
- The adjusted loss widened to $0.75 a share from $0.50, more than expected; fiscal 2027 revenue guidance rose to $141 million from $137 million.
- The stock went from $24.44 to $22.49 in the first minute after the 16:01:48 ET release and was 7.733% lower 10 minutes later, after hours.
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| KMTS | 24.44 | 24.44 | 22.49 | 22.55 | -7.98% | -7.73% |
Kestra Medical Technologies stock is down after hours because its fiscal first-quarter loss widened to $0.75 a share on an adjusted basis, more than analysts expected, even though revenue rose 60% to $31.0 million and the company raised its full-year revenue guidance to $141 million. The stock went from $24.44 to $22.49 in the first minute after the 16:01:48 ET release, a 7.979% drop, and was 7.733% lower after hours, 10 minutes after the 16:01:48 ET release. In the regular session the stock closed at $24.06, up 5.30% on the day (session close).
Kestra Q1 fiscal 2027 earnings: actual vs estimate vs year ago
| Q1 FY2027 | Estimate | Q1 FY2026 | |
|---|---|---|---|
| Revenue | $31.0M | Beat | $19.4M |
| Adjusted EPS | -$0.75 | Smaller loss expected | -$0.50 |
| Gross margin | 56.5% | — | 45.7% |
| GAAP net loss | $44.1M | — | — |
| FY2027 revenue guidance | $141M | — | $137M (prior guidance) |
The quarter ended July 31, 2026. Kestra makes the ASSURE wearable cardioverter defibrillator, a vest-style device for patients at risk of sudden cardiac arrest.
Why a 60% revenue quarter sold off
The business grew and the loss per share still got bigger. Revenue rose 60% and gross margin widened by 10.8 percentage points to 56.5%, yet the adjusted loss deepened from $0.50 to $0.75 a share. Kestra is spending on sales territories and patient coverage faster than its gross profit grows, and the market reacted to the loss line rather than the revenue line.
The guidance raise was modest next to the quarter. Kestra lifted fiscal 2027 revenue guidance by $4 million, to $141 million from $137 million, which still represents 48% growth over fiscal 2026. The company credited market expansion for wearable defibrillators, share gains against competitors, new sales territories, more in-network patients and better revenue collection.
The balance sheet covers the spending for now. Kestra ended the quarter with $244.7 million of cash, cash equivalents and investments, and about $320 million of total liquidity including unused committed term-loan capacity. The quarter's GAAP net loss of $44.1 million equals about 18% of that cash and investments balance.
How the stock traded after the release
| Time (ET) | Price | Change from before |
|---|---|---|
| 16:00 (session close, vs prior close) | $24.06 | +5.30% |
| Before 16:01 (after hours) | $24.44 | — |
| 16:02 (after hours) | $22.49 | -7.979% |
| 16:11 (after hours, 10 minutes after the release) | $22.55 | -7.733% |
The whole drop came in the first minute and barely changed over the next nine, on 19,307 shares.
Why is Kestra Medical Technologies stock down after hours?
Kestra's adjusted loss widened to $0.75 a share from $0.50 a year earlier, more than analysts expected, despite 60% revenue growth to $31.0 million. The stock was 7.733% lower after hours, 10 minutes after the 16:01:48 ET release.
What is Kestra's fiscal 2027 revenue guidance?
Kestra raised fiscal 2027 revenue guidance to $141 million from $137 million, which represents 48% growth over fiscal 2026.
How much cash does Kestra Medical have?
$244.7 million of cash, cash equivalents and investments at July 31, 2026, and about $320 million of total liquidity including unused committed term-loan capacity.
Sources
-
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
— GlobeNewswire
Revenue $31.0 million, up 60%; gross margin 56.5% vs 45.7%; FY27 revenue guidance raised to $141 million from $137 million, 48% growth over FY26.
-
Kestra Medical Technologies falls on wider quarterly loss
— Investing.com
Adjusted loss of $0.75 a share vs $0.50 a year earlier, wider than expected; GAAP net loss $44.1 million; cash and investments $244.7 million; liquidity about $320 million.
-
Kestra Q1 Earnings: Revenue Rises 60% to $31M
— StockTitan
Kestra's Q1 FY27 revenue rose 60% to $31 million and it raised FY27 revenue guidance to $141 million.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes recorded price reactions, search, watchlists, alerts and research tools.
Start Pro Watch live headlines -- free